Not unexpected for the arrangement to end. In reporting terms there are 3 and a bit Qs to go before the revenues go, so the analysts do not need to sharpen their pencils just yet. Timing of announcement was the BTG earnings report.
According to BTG, they wanted to know their customers, money came second.. no contest. Will be interesting to see what kind of rings Ango can draw around its salespeople to stop fishing... or then there is an amicable agreement with BTG on splitting the salesforce... unless Ango acquires new products to fully employ them.
Beads may be only 13% of sales, but 40% of oncology. Margins will go up as beads were a resale, but contribution was likely important.
All the more reason to sell nanoknife in the US. There is nothng to stop selling nanoknife in the US whatsoever. Hopefully with the FDA effectively approving safety of IRE for prostrate, nanoknife will market itself a bit more. Approving just 6 cases is wierd though, but if Ango uses existing sites, they could do those in weeks. The bad news is that "additional trials" will be needed for official marketing clearance. Given the longevity of low-risk prostate cancer patients, any approval based on survival is not worth pursuing! QoL would be a different story... research continues to show nerve sparing...